Allspring Global Investments Holdings LLC Decreases Stock Position in ADMA Biologics Inc $ADMA

Allspring Global Investments Holdings LLC trimmed its position in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 68.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 490,144 shares of the biotechnology company’s stock after selling 1,057,995 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.21% of ADMA Biologics worth $8,764,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of the company. Salomon & Ludwin LLC bought a new position in ADMA Biologics during the 3rd quarter valued at about $25,000. Rothschild Investment LLC lifted its stake in shares of ADMA Biologics by 373.8% during the 3rd quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 1,495 shares during the last quarter. Clearstead Advisors LLC lifted its stake in shares of ADMA Biologics by 55.7% during the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 795 shares during the last quarter. iSAM Funds UK Ltd purchased a new position in ADMA Biologics during the 3rd quarter valued at $34,000. Finally, RiverPark Advisors LLC purchased a new position in ADMA Biologics during the 3rd quarter valued at $35,000. Institutional investors own 75.68% of the company’s stock.

Insider Buying and Selling at ADMA Biologics

In other news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the firm’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the sale, the chief operating officer directly owned 466,600 shares in the company, valued at approximately $7,292,958. This trade represents a 2.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Steve Elms bought 7,000 shares of the stock in a transaction on Thursday, March 5th. The stock was purchased at an average price of $15.67 per share, with a total value of $109,690.00. Following the completion of the purchase, the director owned 2,038,730 shares of the company’s stock, valued at $31,946,899.10. This represents a 0.34% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 3.50% of the stock is currently owned by company insiders.

ADMA Biologics Price Performance

Shares of ADMA Biologics stock opened at $9.19 on Monday. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74. ADMA Biologics Inc has a 1 year low of $7.21 and a 1 year high of $25.67. The firm’s 50-day moving average is $14.79 and its two-hundred day moving average is $16.19. The stock has a market cap of $2.19 billion, a price-to-earnings ratio of 15.32 and a beta of 0.82.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 EPS for the quarter, meeting the consensus estimate of $0.20. The business had revenue of $139.16 million during the quarter, compared to analyst estimates of $139.80 million. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The company’s quarterly revenue was up 18.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.46 EPS. As a group, research analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on ADMA. Cantor Fitzgerald reiterated a “neutral” rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Zacks Research upgraded shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a report on Monday, March 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. Finally, Wall Street Zen upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Two research analysts have rated the stock with a Strong Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $32.00.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.